Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.

@article{Carter2012HealtheconomicRO,
  title={Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.},
  author={John A Carter and Marc F. Botteman},
  journal={Expert review of pharmacoeconomics & outcomes research},
  year={2012},
  volume={12 4},
  pages={425-37}
}
Zoledronic acid is the only bisphosphonate approved for the prevention or delay of skeletal-related events in patients with bone metastases secondary to prostate cancer. Recently, the US FDA and the EMA approved denosumab (a fully human monoclonal antibody) to treat skeletal-related events in bone-metastatic prostate cancer. This article summarizes the cost-effectiveness literature pertaining to these two agents when used in the prevention of skeletal-related events secondary to malignancy… CONTINUE READING
Highly Cited
This paper has 22 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
9 Citations
40 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Xgeva BLA 125320 / 7 Approval Letter . 2010 15 European Medicines Agency . Xgeva

  • K Fizazi, M Carducci, M Smith
  • EPAR Summary for the Public
  • 2012

32 Lothgren M, Bracco A, Lucius B et al

  • November
  • Cost–
  • 2011

Cost – effectiveness of zoledronic acid in the management of skeletal metastases in hormone - refractory prostate cancer patients in France , Germany , Portugal , and The Netherlands

  • J Ford, E Cummins, P Sharma
  • J . Med . Econ .
  • 2011
2 Excerpts

Similar Papers

Loading similar papers…